LAUNXP Biomedical Co., Ltd
TWO: 6876.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chiu-Heng Chen
- Employees
- 35
- Headquarters
- Taichung, Taiwan
- IPO year
- 2024
- Market cap
- NT$1.0B
- Website
- http://www.launxp.com
Loading 6876…
Loading profile data…Frequently asked questions about 6876
What does LAUNXP Biomedical Co., Ltd (6876.TWO) do?
LAUNXP Biomedical Co. Ltd. is engaged in the development of medicines for tumor therapies. It also offers anti-cancer and antiproliferative drugs including virus-like nanoparticles and nanoparticles. The company was founded on September 24, 2015 and is headquartered in Taichung, Taiwan.
Where does 6876.TWO trade?
LAUNXP Biomedical Co., Ltd (6876.TWO) trades on the Taipei Exchange.
What sector is 6876.TWO in?
LAUNXP Biomedical Co., Ltd (6876.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of LAUNXP Biomedical Co., Ltd?
Chiu-Heng Chen is the chief executive officer of LAUNXP Biomedical Co., Ltd (6876.TWO).
Where is LAUNXP Biomedical Co., Ltd headquartered?
LAUNXP Biomedical Co., Ltd is headquartered in Taiwan.
Does 6876.TWO pay a dividend?
LAUNXP Biomedical Co., Ltd (6876.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6876.TWO go public?
LAUNXP Biomedical Co., Ltd (6876.TWO) completed its initial public offering in 2024.